Skip to main content

Slynd Disease Interactions

There are 2 disease interactions with Slynd (drospirenone).


Drospirenone (applies to Slynd) hyperkalemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency, Renal Dysfunction, Liver Disease

The progestin drospirenone (DRSP) has antialdosterone activity, including the potential for hyperkalemia in high-risk patients. The use of DRSP-containing combination hormone is contraindicated in patients with conditions that predispose to hyperkalemia (renal impairment, hepatic impairment, and adrenal insufficiency). Use caution when prescribing these agents to women who regularly take other medications that can increase potassium, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, heparin and aldosterone antagonists. It is recommended to monitor serum potassium concentrations during the first month of dosing in high-risk patients who take strong CYP3A4 inhibitors long-term and concomitantly.


  1. (2001) "Product Information. Yasmin (drospirenone-ethinyl estradiol)." Berlex Laboratories
  2. (2005) "Product Information. Angeliq (drospirenone-estradiol)." Berlex Laboratories
  3. (2010) "Product Information. Beyaz (drospirenone/ethinyl estradiol/levomefolate)." Bayer Pharmaceutical Inc

Estrogens/progestogens (applies to Slynd) retinal thrombosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Estrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.


  1. "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  2. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  3. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  4. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  5. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  7. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  8. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  9. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  11. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  13. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 13 references

Slynd drug interactions

There are 350 drug interactions with Slynd (drospirenone).

Slynd alcohol/food interactions

There is 1 alcohol/food interaction with Slynd (drospirenone).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.